PT  - JOURNAL ARTICLE
AU  - Zandra C. Felix Garza
AU  - Simon P. J. de Jong
AU  - Joseph Gibson
AU  - Alvin X. Han
AU  - Sarah van Leeuwen
AU  - Robert P. de Vries
AU  - Geert-Jan Boons
AU  - Marliek van Hoesel
AU  - Karen de Haan
AU  - Laura van Groeningen
AU  - Hugo D. G. van Willigen
AU  - Elke Wynberg
AU  - Godelieve J. de Bree
AU  - Amy Matser
AU  - Lia van der Hoek
AU  - Maria Prins
AU  - Neeltje A. Kootstra
AU  - Dirk Eggink
AU  - Brooke E. Nichols
AU  - Menno D. de Jong
AU  - Colin A. Russell
TI  - Impacts of the COVID-19 pandemic on future seasonal influenza epidemics
AID  - 10.1101/2022.02.05.22270494
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.02.05.22270494
4099  - http://medrxiv.org/content/early/2022/02/06/2022.02.05.22270494.short
4100  - http://medrxiv.org/content/early/2022/02/06/2022.02.05.22270494.full
AB  - Seasonal influenza viruses typically cause annual epidemics worldwide infecting 5-15% of the human population1. However, during the first two years of the COVID-19 pandemic, seasonal influenza virus circulation was unprecedentedly low with very few reported infections2. The lack of immune stimulation to influenza viruses during this time, combined with waning antibody titres to previous influenza virus infections, could lead to increased susceptibility to influenza in the coming seasons and to larger and more severe epidemics when infection prevention measures against COVID-19 are relaxed3,4. Here, based on serum samples from 165 adults collected longitudinally before and during the pandemic, we show that the waning of antibody titres against seasonal influenza viruses during the first two years of the pandemic is likely to be negligible. Using historical influenza virus epidemiological data from 2003-2019, we also show that low country-level prevalence of each influenza subtype over one or more years has only small impacts on subsequent epidemic size. These results suggest that the risks posed by seasonal influenza viruses remained largely unchanged during the first two years of the COVID-19 pandemic and that the sizes of future seasonal influenza virus epidemics will likely be similar to those observed before the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA.X.H., Z.C.F.G. and C.A.R. were supported by ERC NaviFlu (No. 818353). J.G. and C.A.R. were supported by NIH R01 (5R01AI132362-04). C.A.R. was also supported by an NWO Vici Award (09150182010027). R.P.dV. was supported by ERC starting grant 802780 and a Beijerinck Premium of the Royal Dutch Academy of Sciences. GJB was supported by the Netherlands Organization for Scientific Research (NWO TOPPUNT 718.015.003) and by an ERC advanced grant (101020769). The RECoVERED cohort is supported by NWO ZonMw (No. 10150062010002). The Amsterdam Cohort Studies on HIV infection and AIDS, a collaboration between the Public Health Service Amsterdam, the Amsterdam UMC of the University of Amsterdam, Medical Center Jan van Goyen and the HIV Focus Center of the DC-Clinics, are part of the Netherlands HIV Monitoring Foundation and financially supported by the Center for Infectious Disease Control of the Netherlands National Institute for Public Health and the Environment.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Amsterdam Cohort Studies on HIV infection and AIDS was approved by the Medical Ethics Committee of the Amsterdam University Medical Centre of the University of Amsterdam, the Netherlands (MEC 07/182). The RECoVERED study was approved by the medical ethical review board of the Amsterdam University Medical Centre (NL73759.018.20).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced are available online at the project GitHub repository. https://github.com/AMC-LAEB/waning-immunity-to-flu